Antibodies
Sponsors
Shengjing Hospital of China Medical University, Guangyuan Central hospital, Jan van Breemen Instituut, Center of Molecular Immunology (CIM)
Conditions
Advanced Lung Cancer Non-small Cell Lung CancerAdvanced Lung Cancer Small Cell Lung CancerBreast carcinoma in stage IV or progressive metastatic diseaseColon adenocarcinoma phase IV or evolvable metastatic diseaseInvasive candidiasisPersistent or relapsing ovary epithelial cancerSolid tumors
Solid tumorsThrombotic disease
Early Phase 1
Study for the value of detection of Candida-specific antibodies in early diagnosis of invasive candidiasis
Active, not recruitingChiCTR1900022330
Start: 2019-04-01Updated: 2019-04-08
Predictive value of antiphospholipid antibodies in hospitalized patients with potential thrombus risk
RecruitingChiCTR2100045122
Start: 2021-04-12Updated: 2021-11-08
Phase 1
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I.
Active, not recruitingRPCEC00000036
Start: 2008-01-02Target: 15Updated: 2026-03-30
Dose scale-up and cohort expansion with the therapeutic mAb 14F7
Active, not recruitingRPCEC00000204
Start: 2016-01-01Target: 60Updated: 2026-03-30
Phase 2
1E10 anti-idiotype vaccine, metastatic colon, phase II.
Active, not recruitingRPCEC00000006
Start: 2002-07-19Target: 40Updated: 2026-03-30
1E10 anti-idiotype vaccine, metastatic breast cancer, phase II
Active, not recruitingRPCEC00000008
Start: 2003-09-15Target: 80Updated: 2026-03-30
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients
Active, not recruitingRPCEC00000009
Start: 2006-09-27Target: 176Updated: 2026-03-30
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients
Active, not recruitingRPCEC00000010
Start: 2005-03-03Target: 88Updated: 2026-03-30